NEW HAVEN, Conn., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Kleo Pharmaceuticals, Inc., a targeted immunotherapy company developing fully synthetic bispecific therapies to redirect, enhance or replace antibodies, is presenting preclinical data today on KPMW135, a novel CD3 x CD20 bispecific molecule developed with Kleo’s multi-targeted antibody therapy enhancer (MATE™) conjugation platform.
NEW HAVEN, Conn., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Kleo Pharmaceuticals, Inc., a targeted immunotherapy company developing fully synthetic bispecific therapies to redirect, enhance or replace antibodies, announced that it will present today to local stakeholders at the Bioscience Pipeline & Innovation in Connecticut in the Age of COVID conference on Monday, September 21, 2020 at 2:00 p.m. ET. The event is being sponsored by BioCT, PhRMA and the Bipartisan Bioscience Caucus.
NEW HAVEN, Conn., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Kleo Pharmaceuticals, a targeted immunotherapy company developing fully synthetic bispecific therapies to redirect, enhance or replace antibodies, announced today that its lead compound, KP1237, has received Orphan Drug designation from the U.S. Food and Drug Administration (FDA) in multiple myeloma. KP1237 is an antibody-redirecting molecule (ARMä) that targets CD38, a clinically validated target for multiple myeloma.
NEW HAVEN, Conn., May 21, 2020 (GLOBE NEWSWIRE) -- Kleo Pharmaceuticals, Inc., a leading company in the field of developing next-generation, fully synthetic bispecific compounds designed to emulate or enhance the activity of biologics, and Celularity, Inc., a leading developer of allogeneic, or “off-the-shelf”, natural killer (NK) cell therapies, today announced a preclinical research collaboration to rapidly advance synergistic combinations of each company’s technology platform as potential treatments for COVID-19 and multiple myeloma.
NEW HAVEN, Conn., May 15, 2020 (GLOBE NEWSWIRE) -- Kleo Pharmaceuticals, Inc., a leading company in the field of developing next-generation, fully synthetic bispecific compounds designed to emulate or enhance the activity of biologics, today announced preclinical data for the company’s lead program, KP1237 in combination with autologous, cytokine-induced, memory-like (CIML) natural killer (NK) cells with low dose IL-2 in multiple myeloma (MM). KP1237 is a CD38-targeting antibody recruiting molecule (ARMTM). These data, to be presented as a poster at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting being held May 29–31, will support the initiation of an upcoming Phase 1/2 clinical trial for MM patients receiving an autologous stem cell transplant (ASCT), who remain minimum residual disease positive (MRD+)